Further experimental studies have shown that STC2 in ER+ breast cancer tissues had a significant higher expression than that in ER-breast cancer tissues, and STC2 expression had no significant differences in age, pathological type, tumor size, PR expression, and HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.